Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote & News

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 450 6464

Website: www.crinetics.com

Address:

6055 Lusk Boulevard, San Diego, United States

StocktwitsEarnings Aug. 3 at 8:15 PM

$CRNX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.14 up 7.32% YoY • Reported revenue of $25.12M up 2336.28% YoY

0 · Reply

Breakout_Hunter1 Jul. 24 at 9:14 PM

Two months ago, I shared this watchlist with you… This month’s focus: $INHD +3000%+ $VEEE +400%~450% $SOBR +around 100% $WBUY +70%~80% $CRNX +50%~60% Not every setup will play out the same way, but the biggest opportunities often come from names that are still being overlooked. Stay focused. Stay patient. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

Breakout_Hunter1 Jul. 23 at 7:32 PM

This month, I’m watching… 5 stocks with strong potential heading into 2027. The focus is simple: finding companies with improving momentum, early market attention, and asymmetric upside potential. My watchlist: $VEEE + 400% ~ 450% $SOBR + around 100% $WBUY +70% ~ 80% $CRNX + 50% ~ 60% $ATAI + 40% ~ 50% Not every stock will follow the same path, but the biggest moves often start when fewer people are paying attention. The market rewards preparation, patience, and being early. Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened.

0 · Reply

GEEK102 Jul. 22 at 3:38 PM

$ATER $GRPN $SOUN $ABTC $CRNX You insider piece of cum fget

0 · Reply

55X_ROI_Q1_2026 Jul. 22 at 12:27 AM

$SLS $VRTX x $CRNX proxy details: How Buyouts Happen.

1 · Reply

Breakout_Hunter1 Jul. 20 at 8:09 PM

Five stocks with market capitalizations under $10 billion are on my watchlist. Not because they've already made the biggest move... But because I believe they still have the potential to create outsized returns over the coming years. This month's focus: 1. $FBRX +129% 2. $CRNX +117% 3. $TRAX +96% 4. $PHOE +78% 5. $ALIT +58% The biggest winners are rarely obvious when they're still small. That's why I spend more time building my watchlist than chasing headlines. Next alert is coming soon. If you're not following with notifications on, you're likely seeing the move after it already happened.

0 · Reply

Breakout_Hunter1 Jul. 19 at 7:25 PM

July Trading Recap! Despite a challenging market environment, several names delivered strong moves this month. Performance highlights: $INHD +3000% $GMM +150%~200% $NXTC +around 150% $FBRX +120%~130% $CRNX +around 120% Strong momentum often comes from finding opportunities before they become crowded. The focus is always on identifying trends, understanding catalysts, and managing risk along the way. Not every setup works, but preparation creates opportunities when the market moves. Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened.

0 · Reply

Steve_TheBull_Rogers Jul. 19 at 2:46 PM

$CRNX Someone knew. Someone traded on inside information They turned $5,442 into $1,571,835 Percentage gain: approximately 28,783% Someone always knows! Uggggh 5k into 1.5M in profit is insane

3 · Reply

Terrytyler Jul. 18 at 2:30 AM

$GMM $NXTC $CRNX $NVVE $FBRX Those all already run.

0 · Reply

Breakout_Hunter1 Jul. 17 at 8:41 PM

July Stock Watchlist: Stocks Worth Watching Momentum has been building in several small and mid-cap names this month. These are the stocks I’m keeping on my radar: $GMM +150%~200% $NXTC +150%~200% $CRNX +115%~120% $NVVE +Approximately 100% $FBRX +100%~110% Strong moves always attract attention, but the key is understanding the catalyst, the trend, and whether the story still has room to develop. Not every runner continues higher. The goal is finding opportunities before the crowd returns. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

Crinetics Pharmaceuticals Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 1 hour ago

Crinetics Pharmaceuticals Quarterly report: Q2 2026

Aug 3, 2026, 4:05 PM EDT - 1 day ago

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 31, 2026, 8:00 AM EDT - 4 days ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

2026-07-28T00:30:25.000Z - 7 days ago

Crinetics downgraded to Neutral from Buy at UBS

Jul 21, 2026, 11:03 AM EDT - 14 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)

ESI TCBK VEEE

Jul 21, 2026, 8:00 AM EDT - 14 days ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Jul 21, 2026, 7:00 AM EDT - 14 days ago

Crinetics Pharmaceuticals Slides: Corporate presentation

Jul 10, 2026, 8:00 AM EDT - 25 days ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

2026-07-08T13:20:58.000Z - 27 days ago

Crinetics downgraded to Hold from Buy at Stifel

Jul 8, 2026, 3:00 AM EDT - 27 days ago

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

VRTX

2026-07-08T01:00:09.000Z - 27 days ago

Crinetics downgraded to In Line from Outperform at Evercore ISI

2026-07-07T20:16:07.000Z - 4 weeks ago

Crinetics downgraded to Hold from Buy at TD Cowen

VRTX

2026-07-07T16:40:16.000Z - 4 weeks ago

Crinetics downgraded to Market Perform from Outperform at Citizens

2026-07-07T16:05:42.000Z - 4 weeks ago

Crinetics rises 98.8%

2026-07-07T14:06:08.000Z - 4 weeks ago

Crinetics rises 98.8%

2026-07-07T14:05:57.000Z - 4 weeks ago

Crinetics downgraded to Hold from Buy at Jefferies

2026-07-07T14:00:20.000Z - 4 weeks ago

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

ASND BCRX VRTX

Jul 7, 2026, 9:38 AM EDT - 4 weeks ago

Crinetics shares surge after Vertex agrees to $10B cash buyout

VRTX

2026-07-07T13:35:29.000Z - 4 weeks ago

Crinetics downgraded to Hold from Buy at JonesResearch

Jul 7, 2026, 9:28 AM EDT - 4 weeks ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

VRTX

2026-07-07T12:36:21.000Z - 4 weeks ago

Crinetics downgraded to Neutral from Overweight at Piper Sandler

2026-07-07T11:46:02.000Z - 4 weeks ago

Vertex adds ‘genuine fifth commercial pillar’ with deal, says H.C. Wainwright

VRTX

2026-07-07T11:40:19.000Z - 4 weeks ago

Crinetics downgraded to Neutral from Buy at H.C. Wainwright

Jul 7, 2026, 7:33 AM EDT - 4 weeks ago

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

VRTX

2026-07-07T10:50:24.000Z - 4 weeks ago

Crinetics price target raised to $85 from $62 at Baird

VRTX

Jul 7, 2026, 6:35 AM EDT - 4 weeks ago

Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today's Market

MU RIVN SPCX

2026-07-07T09:55:09.000Z - 4 weeks ago

Crinetics downgraded to Perform from Outperform at Oppenheimer

VRTX

Jul 6, 2026, 5:02 PM EDT - 4 weeks ago

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

VRTX

Jul 6, 2026, 4:10 PM EDT - 4 weeks ago

Vertex to buy Crinetics in $10 billion deal

VRTX

Jul 6, 2026, 4:04 PM EDT - 4 weeks ago

Vertex to Acquire Crinetics Pharmaceuticals

VRTX

Jul 6, 2026, 8:00 AM EDT - 4 weeks ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Jul 6, 2026, 8:00 AM EDT - 4 weeks ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Jun 30, 2026, 4:05 PM EDT - 5 weeks ago

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

Jun 18, 2026, 11:00 AM EDT - 6 weeks ago

Crinetics Pharmaceuticals Transcript: AGM 2026

Jun 14, 2026, 2:45 PM EDT - 7 weeks ago

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Jun 2, 2026, 4:05 PM EDT - 2 months ago

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities

Jun 2, 2026, 4:55 AM EDT - 2 months ago

Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

May 22, 2026, 4:05 PM EDT - 2 months ago

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Crinetics Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Crinetics Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Crinetics Pharmaceuticals Slides: Q1 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 5:13 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Apr 8, 2026, 4:05 PM EDT - 4 months ago

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Mar 26, 2026, 4:05 PM EDT - 4 months ago

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Mar 4, 2026, 1:50 PM EST - 5 months ago

Crinetics Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:50 PM EST - 5 months ago

Crinetics Pharmaceuticals Slides: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:30 PM EST - 5 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Crinetics Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Crinetics Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Crinetics Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 5 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 5, 2026, 4:05 PM EST - 6 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Jan 26, 2026, 5:00 PM EST - 6 months ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 22, 2026, 4:05 PM EST - 6 months ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 13, 2026, 12:45 PM EST - 7 months ago

Crinetics Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 7 months ago

Crinetics Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:05 PM EST - 7 months ago

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 9:22 PM EST - 7 months ago

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 5, 2026, 4:02 PM EST - 7 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 5, 2026, 8:30 AM EST - 7 months ago

Crinetics Pharmaceuticals Transcript: Study Update

Jan 5, 2026, 8:30 AM EST - 7 months ago

Crinetics Pharmaceuticals Press release: Study Update

Jan 5, 2026, 8:30 AM EST - 7 months ago

Crinetics Pharmaceuticals Slides: Study Update

Jan 5, 2026, 8:00 AM EST - 7 months ago

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Jan 4, 2026, 4:00 PM EST - 7 months ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Dec 18, 2025, 4:05 PM EST - 8 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:05 PM EST - 8 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Dec 10, 2025, 4:34 PM EST - 8 months ago

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 8:00 AM EST - 8 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Nov 20, 2025, 4:05 PM EST - 9 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Nov 10, 2025, 4:28 PM EST - 9 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 4:30 PM EST - 9 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Crinetics Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Crinetics Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Crinetics Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 9 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Oct 10, 2025, 4:41 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 4:05 PM EDT - 10 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 25, 2025, 6:00 PM EDT - 11 months ago

Crinetics Pharmaceuticals Transcript: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 11 months ago

Crinetics Pharmaceuticals Press release: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 11 months ago

Crinetics Pharmaceuticals Slides: FDA Announcement

Sep 25, 2025, 5:30 PM EDT - 11 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Sep 10, 2025, 4:30 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 21, 2025, 8:45 AM EDT - 1 year ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Aug 11, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 13, 2025, 5:45 PM EDT - 1 year ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 10, 2025, 4:28 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

StocktwitsEarnings Aug. 3 at 8:15 PM

$CRNX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.14 up 7.32% YoY • Reported revenue of $25.12M up 2336.28% YoY

0 · Reply

Breakout_Hunter1 Jul. 24 at 9:14 PM

0 · Reply

Breakout_Hunter1 Jul. 23 at 7:32 PM

0 · Reply

GEEK102 Jul. 22 at 3:38 PM

$ATER $GRPN $SOUN $ABTC $CRNX You insider piece of cum fget

0 · Reply

55X_ROI_Q1_2026 Jul. 22 at 12:27 AM

$SLS $VRTX x $CRNX proxy details: How Buyouts Happen.

1 · Reply

Breakout_Hunter1 Jul. 20 at 8:09 PM

0 · Reply

Breakout_Hunter1 Jul. 19 at 7:25 PM

0 · Reply

Steve_TheBull_Rogers Jul. 19 at 2:46 PM

$CRNX Someone knew. Someone traded on inside information They turned $5,442 into $1,571,835 Percentage gain: approximately 28,783% Someone always knows! Uggggh 5k into 1.5M in profit is insane

3 · Reply

Terrytyler Jul. 18 at 2:30 AM

$GMM $NXTC $CRNX $NVVE $FBRX Those all already run.

0 · Reply

Breakout_Hunter1 Jul. 17 at 8:41 PM

0 · Reply

livinginmyvandownriver Jul. 16 at 9:26 PM

$ATAI $CRNX $FBRX $GMM $JZXN PSIL 52 week high today

0 · Reply

Breakout_Hunter1 Jul. 16 at 8:01 PM

This could be one of the most interesting setups to watch heading into the second half of 2026. Small and mid-cap names can move quickly when momentum, catalysts, and market attention align. My July watchlist: $ATAI $5.0 → $7.1 +40% $CRNX $38 → ~$84 +120% $FBRX $21 → ~$43 +100% $GMM $2.0 → ~$6 +200% $JZXN $1.3 → ~$2.5 +90% Not every setup will continue higher, but these are the types of names I’m tracking for potential momentum and asymmetric opportunities. The key is patience. Watch the trend. Manage risk. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

WallStWireAds Jul. 16 at 2:33 PM

$NVCT $TGTX $VRTX $JBIO $CRNX

0 · Reply

Stocks_and_Stacks Jul. 16 at 4:32 AM

First off 📚 who’s all up late studying charts and getting ready for tomorrow? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp, bulls! Huge congrats to everyone riding these top 5 movers today 🤔 volume rebounds, clinical momentum, and sector rotation powered solid green! $LCID +28.8% – Lucid Group surging on EV rebound and denial of bankruptcy rumors with strong buying.🤔📚 $CHRN +28.8% – ChronoScale climbing on high-volume speculative interest. $CRNX + strong move – Crinetics Pharmaceuticals extending gains on pipeline momentum. $SMCI + AI – Super Micro lifting on data center news. $SKHY + memory – SK Hynix building on debut strength amid chip demand. Solid mid-week stacking wins, bulls. 💪 Who else is celebrating big gains today? Drop your winners below. Just our opinions and not financial advice 🤝 #TopMovers #BullMarket #Stocks #BangerAlerts #EVRally

0 · Reply

Breakout_Hunter1 Jul. 15 at 8:09 PM

Stocks I’m watching in July. 👀 These names have shown strong momentum recently, and I’m watching how they handle key levels after major moves. Current watchlist: $CRNX $38 → $83.7 (+120% approx.) $FBRX $21 → ~$43 (+100% approx.) $TRAX $18 → ~$33 (+80% approx.) $GMM $2 → ~$4.5 (+120% approx.) $NXTC $2 → ~$9 (+300% approx. pre-market high) Big moves always attract attention, but the next opportunity usually comes from finding quality setups before the crowd arrives. Watching price action, momentum, and where buyers step back in. Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened.

0 · Reply

WallStWireAds Jul. 15 at 6:03 PM

$ENTX https://www.benzinga.com/content/60467397/after-crinetics-10-billion-deal-could-entera-bio-be-next-category-defining-oral-peptide-story $CRNX $ERNA $AZN $LLY

0 · Reply

Night_Owl_Biotech Jul. 15 at 12:39 AM

$CELC is now the latest addition to our list of 23 commercial-stage oncology focused bios with market caps north of $450MM. Congratulations to CELC No one asked but attached is a comparison of CELC's valuation as a multiple of 5 year (FY28 - 32) & 8-year (FY28 - 35) analyst consensus revenue estimates to 4 very recent peer M&A oncology & non-oncology transactions (all nearing commercial-stage like CELC yesterday). The comp is not perfect but does provide a barometer of CELC potential if analyst estimates are credible & if Gedatolisib is worth peer M&A multiples should CELC exit. This is not investment advice. We're merely sharing 1 analysis of many needed to assess potential. We will update CELC's multiples to its peer oncology focused bios shortly. $CRNX $XBI $IBB $APGE

0 · Reply

WallStWireAds Jul. 14 at 4:18 PM

$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX

0 · Reply

drpgadan59 Jul. 14 at 1:31 PM

$CRNX ready for $85

0 · Reply

Market_Cipher Jul. 13 at 8:01 PM

This week's trading watchlist is ready. These names have shown strong momentum recently, and I'm watching closely to see whether they can continue building on it. Current watchlist: $CRNX $42 → $83.6 (+99%) $FBRX $21 → $43.9 (+109%) $TRAX $18.5 → $36.2 (+96%) $WRAP $1.45 → $2.46 (+70%) $WBX $3.40 → $5.37 (+58%) Past performance doesn't guarantee the next move. I'm more interested in how these stocks react around key levels than chasing what has already happened. Risk management always comes first. If you want to see the high-conviction stocks I'm watching, my full portfolio, and every trade I make... Head to my profile.

0 · Reply

Breakout_Hunter1 Jul. 13 at 7:24 PM

These stocks have been some of the strongest performers this month. Big gains don't guarantee what's next, but strong momentum is always worth keeping on the watchlist. Recent moves: $CRNX $38 → $83.6 (+120%) $FBRX $21 → $43.9 (+109%) $TRAX $18.5 → $36.2 (+96%) $WRAP $1.45 → $2.46 (+70%) $WBX $3.40 → $5.37 (+58%) Chasing isn't my strategy. I'm more interested in finding the next quality setup before it becomes obvious. The best opportunities usually appear before everyone is talking about them. Next alert is coming soon. If you're not following with notifications on, you're likely seeing the move after it already happened.

0 · Reply

EmilyMorgan1010 Jul. 13 at 7:08 PM

$CRNX I'm happy to have made a profit on another trade.

0 · Reply

Market Cap	8.81B
Revenue (ttm)	7.70M
Net Income (ttm)	-465.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,043.12%
Debt to Equity Ratio	0.00

Volume	2,725,845
Avg Vol	4,268,688
Day's Range	N/A - N/A
Shares Out	105.44M
Stochastic %K	55%
Beta	0.23
Analysts	Sell
Price Target	$85.00